Amgen

1Q Revenues: $3.6 billion (-2%)

1Q Earnings: $1.1 billion (+2%)

Comments: Worldwide sales of Aranesp decreased 25% to $761 million, with U.S. sales down 38% to $405 million due to prescribing restrictions as a result of adverse cardiovascular events. Epogen sales were $554 million (-11%) due to a reduction in dose/utilization due to ESA label changes and implementation of the Erythropoietin Monitoring Policy (EMP). Combined sales of Neulasta and Neupogen were $1.1 billion (+7%). Sales of Enbrel were $951 million (+30%). Sensipar sales were $133 million (+27%). R&D expenses were $661 million (-18%), reflecting cost recoveries derived from licensing transactions with Daiichi Sankyo and Takeda in Japan.